Managed care cost containment strategies

Disease management programs represent another pharmaceutical industry strategy to counter managed care cost-containment efforts. Offered by... 

SD Horn, PD Sharkey, DM Tracy, CE Horn, B James, F Goodwin. Intended and unintended consequences of HMO cost-containment strategies results from the managed care outcomes project. Am J Managed Care 2 253-264, 1996. 

To more fully understand the impact of managed care on the pharmaceutical industry, a look at managed care s cost-containment strategies and continued movement toward multiple payers will be presented first, followed by the influential market dynamics of increased competition and changing demographics. Concluding the section will be a discussion of how these factors have impacted the pharmaceutical industry s research and development priorities and product life cycles. 

In addition to the influence of a growing geriatric market segment on pharmaceutical industry research and development, each of the other managed care and market influences -cost-containment strategies, multiple payers and market competition - have collectively impacted pharmaceutical research and development. The pharmaceutical industry is highly... 

In addition to cost-containment strategies, managed care is impacting the pharmaceutical industry through a continued movement toward multiple payers of healthcare. The make-up of the payer... 

These laws illustrate the lack of understanding and support among part of the public for many of the pharmacy benefit management strategies now taking place. Such restrictions and disclosure requirements can be expected to continue and to become more widespread if the pubhc perceives PBM and payer activities as being motivated more by cost containment than by health care quahty considerations. 

---